خانه › سرطان ریه غیرسلول کوچک › اورگان › Portland
آزمایش‌های بالینی سرطان ریه غیرسلول کوچک در Portland، OR
46 مطالعه برای سرطان ریه غیرسلول کوچک در مراکز Portland (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
در حال جذب شرکت‌کنندهمرحله 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 مایل فاصله
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
در حال جذب شرکت‌کنندهمرحله 1/2
- Oregon Health & Science University (OHSU), Portland
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Exelixis Clinical Site #51, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
در حال جذب شرکت‌کنندهمرحله 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Site 02, Portland
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- ALX Center 6, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- PHN-012-001 Site, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
در حال جذب شرکت‌کنندهمرحله 1
- Research Site, Portland
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 3
- OHSU Knight Cancer Institute, Northwest, Portland
- Providence Cancer Institute Franz Clinic, Portland
- OHSU Knight Cancer Institute, East Portland, Portland
- و 6 مورد دیگر
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
در حال جذب شرکت‌کنندهمرحله 3
- Oregon Health and Science University ( Site 0052), Portland
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
در حال جذب شرکت‌کنندهمرحله 2
- Providence Cancer Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Northwest Cancer Specialists, P.C., Portland
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 2
- Oregon Health And Science University, Portland
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 2
- Oregon Health And Science University, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Research Site, Portland
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- و 1 مورد دیگر
Pan-tumor MRD Study
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Oregon Health & Science University (OHSU), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
در حال جذب شرکت‌کنندهمرحله 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
- Oregon Health and Science University, Portland
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
در حال جذب شرکت‌کنندهمرحله 3
- Clinical Study Site, Portland
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
در حال جذب شرکت‌کنندهمرحله 3
- Providence Cancer Institute, Portland
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
در حال جذب شرکت‌کنندهمرحله 2/3
- Local Institution - 007-885B, Portland
- Local Institution - 007-885A, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
در حال جذب شرکت‌کنندهمرحله 1
- Providence Cancer Institute, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Oregon Health and Science University, Portland
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
در حال جذب شرکت‌کنندهمرحله 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
در حال جذب شرکت‌کنندهمرحله 1/2
- Compass Oncology - Rose Quarter, Portland
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
در حال جذب شرکت‌کنندهمرحله 1/2
- Providence Cancer Institute, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- و 1 مورد دیگر
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
در حال جذب شرکت‌کنندهمرحله 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- و 2 مورد دیگر
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
در حال جذب شرکت‌کنندهمرحله 2
- USA15-0, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- و 2 مورد دیگر
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- و 1 مورد دیگر
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
در حال جذب شرکت‌کنندهمرحله 2
- Providence Health & Services - Oregon, Portland
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- و 2 مورد دیگر
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Kaiser Permanente Northwest, Portland
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Providence Cancer Institute, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
در حال جذب شرکت‌کنندهمرحله 1/2
- Oregon Health & Science University, Portland
آزمایش‌های سرطان ریه غیرسلول کوچک در سایر شهرها
- Houston, TX145 مطالعه
- New York City, NY121 مطالعه
- Arlington, VA104 مطالعه
- Nashville, TN97 مطالعه
- Boston, MA90 مطالعه
- Los Angeles, CA87 مطالعه
- St. Louis, MO73 مطالعه
- Chicago, IL61 مطالعه
- Baltimore, MD60 مطالعه
- San Antonio, TX59 مطالعه
- Columbus, OH57 مطالعه
- Washington, DC55 مطالعه
سایر مطالعات در Portland
- سرطان (همه انواع)34 مطالعه
- سرطان پستان33 مطالعه
- سرطان پروستات33 مطالعه
- سرطان متاستاتیک29 مطالعه
- سرطان کولورکتال28 مطالعه
- سرطان تخمدان27 مطالعه
- سرطان ریه26 مطالعه
- لوکمیه حاد میلویید25 مطالعه
- سرطان آندومتر24 مطالعه
- کارسینوم سلول سنگفرشی سر و گردن19 مطالعه
- سرطان لوزالمعده19 مطالعه
- نارسایی قلبی17 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 6 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.